Navigation Links
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Date:10/24/2007

, safety, tolerability and food effect of R7128 in healthy volunteers and in patients chronically infected with HCV genotype 1. This adaptive Phase 1 study is comprised of three parts:

Part 1 is a single ascending dose study of R7128 conducted in 46 healthy volunteers. The primary objective of Part 1 is to assess the safety, tolerability and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of Part 1 is to explore the effect of food on the pharmacokinetics of R7128. Results from the single ascending dose portion of the study indicated that all doses of R7128 studied (500 mg to 9000 mg) were generally safe and well-tolerated. All patients completed the study, and none experienced gastrointestinal adverse events or serious adverse events during the study. No hematological or laboratory abnormalities of clinical significance were noted.

Part 2 is a multiple ascending dose study of R7128 conducted in 40 patients chronically-infected with HCV genotype 1 who previously failed interferon therapy. The primary objective of Part 2 is to assess the safety, tolerability and pharmacokinetics of R7128 after once-daily (QD) or twice- daily (BID) dosing for 14 days. The secondary objective is to assess antiviral activity by measuring the change in HCV RNA. Preliminary data from the multiple ascending dose portion of the study indicated that R7128 demonstrated potent, dose-dependent antiviral activity in four patient cohorts receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. Patients receiving 1500 mg BID demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of viral rebound in any dose cohort during the 14 days of dosing. R7128 was generally safe and well tolerated. There were no serious adverse events, no adverse events requiring dose modification, no dose-related gastrointestinal adverse events and no clinically significant chan
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
10. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
11. Point of Care Strep Tests Speed Treatment, Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... has announced the addition of the "Investigation ... report to their offering. Developed by ... of Novolog) is an important drug for the ... aspart, as a fast- acting insulin analog, starts ...
(Date:8/28/2015)... 2015  IP Shakti, LLC, today announced that it has ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... corporate identity signifies our transformation into a company focused on ... for patent claim validity." ... AIA Shield™ platform, the Company commenced a corporate re-branding initiative ...
(Date:8/28/2015)... and PITTSBURGH , ... MYL ) today announced that its shareholders have ... (NYSE: PRGO ; TASE) and the related ... at an extraordinary general meeting of shareholders held ... votes cast at the extraordinary general meeting. In ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... Heska Corporation (NASDAQ: HSKA ), a provider ... , today announced that Robert Grieve, Heska,s Chairman and CEO, ... 2011 at 10:30 a.m. PT / 1:30 p.m. ET.  The ... Hotel in Los Angeles. (Logo: http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ...
... Md., Sept. 13, 2011 Sodexo, Inc., a leader ... with Healthsense, Inc.  As a part of the agreement, ... existing senior living client communities – expanding Sodexo,s current ... Life for all of the people and communities they ...
Cached Medicine Technology:Heska to Present at LD MICRO Invitational on September 22, 2011 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 3
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic Informed Consent ... – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic ... , Clinical trial sites can now use audio, video and interactivity ...
(Date:8/29/2015)... ... 29, 2015 , ... Targeted therapies, made possible by a ... patients, according to a newly published report. Surviving Mesothelioma has more on the ... , The authors of the new paper focus on several types of targeted ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... ProDrop ... X . Each preset contains 15 seconds of unique footage that users can shrink ... rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced ... Arterosil and Arterosil HP, and that all claims and counterclaims have been irrevocably ... LLC (VHS) in the United States District Court for the Southern District of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists are ... children helping children, a thank you to the many creative and generous ways ... the United Methodist initiative to end malaria deaths. , The Columbus Zoo and ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3
... found those with multiple auras had seizures arising from one ... People with epilepsy who experience multiple types of auras may ... arise from one area of the brain, a U.S. study ... of Neurology , ,included 31 epilepsy patients who experienced ...
... also been linked to Alzheimer,s, researchers note , FRIDAY, ... apolipoprotein E (APOE) e4 gene variant -- associated with ... types of dementia -- are more likely to develop ... gene variant, a U.S. study finds. , Researchers at ...
... The female sex hormone estrogen turns on a gene linked ... , The cancer biology team from UQ,s Diamantina Institute ... help explain the link between breast cancer and high levels ... ability of estrogen to switch this gene on is important ...
... THURSDAY, Aug. 23 (HealthDay News) -- After a heart attack, ... a new study finds. , In fact, recent heart attack ... diabetes compared with the general population and more than 15 ... the report in the Aug. 25 issue of The ...
... The smell fades with time, study shows , THURSDAY, Aug. ... can affect drinking water,s odor but not for long, a ... instead of copper piping, and scientists are trying to evaluate ... In this study, researchers evaluated several types of plastic piping. ...
... from the Sahlgrenska Academy has established that surgery reduces ... follow up has shown that mortality is significantly lower ... do not. , The results are published today ... show for the first time that surgery against obesity ...
Cached Medicine News:Health News:Some Epilepsy Patients Are Good Candidates for Surgery 2Health News:Gene Tied to Post-Op Delirium in Elderly 2Health News:Heart Attack Boosts Diabetes Risk 2Health News:Surgery for severe obesity saves lives 2
... Single Use linear stapler with LACTOMER™ ... Suture™ PREMIUM POLY CS™-57 disposable surgical ... of a temporary opening, such as ... section, or when transecting muscle tissue, ...
... Units With Titanium Staples for ... (Single Use Reloadable Stapler with ... Suture™ PREMIUM MULTIFIRE TA™ stapler ... pediatric and thoracic surgical procedures ...
... Single Use Loading Units for ... (Single Use Reloadable Staplers with ... Suture™ TA™ Reloadable staplers has ... and thoracic surgical procedures for ...
... linear stapler for resection, transection and anastomosis ... MULTIFIRE GIA™ 60 and 80 single use ... 80 single use loading units and the ... use surgical stapler with MULTIFIRE SGIA™ 60 ...
Medicine Products: